MA39710A - Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin - Google Patents
Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestinInfo
- Publication number
- MA39710A MA39710A MA039710A MA39710A MA39710A MA 39710 A MA39710 A MA 39710A MA 039710 A MA039710 A MA 039710A MA 39710 A MA39710 A MA 39710A MA 39710 A MA39710 A MA 39710A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- inflammatory bowel
- bowel disease
- topical composition
- probiotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une composition topique contenant un probiotique et de l'acide hyaluronique ou un sel pharmaceutiquement acceptable de celui-ci, pour une utilisation dans le traitement et/ou la prévention d'une maladie inflammatoire de l'intestin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20140751 | 2014-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39710A true MA39710A (fr) | 2015-10-29 |
Family
ID=50981755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039710A MA39710A (fr) | 2014-04-23 | 2015-04-21 | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
Country Status (6)
Country | Link |
---|---|
US (2) | US11464814B2 (fr) |
EP (1) | EP3134072A1 (fr) |
JP (1) | JP2017513906A (fr) |
CA (1) | CA2944118C (fr) |
MA (1) | MA39710A (fr) |
WO (1) | WO2015162570A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
MA39710A (fr) * | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
MA45327A (fr) | 2016-05-13 | 2019-03-20 | Sofar Spa | Utilisation de probiotiques pour améliorer l'absorption des protéines |
MA45288A (fr) | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
IT201600131819A1 (it) * | 2016-12-28 | 2018-06-28 | Metis Healthcare S R L | Preparazione per spray orale |
IT201700101704A1 (it) * | 2017-09-12 | 2019-03-12 | Sofar Spa | Nuovo uso per trattamento delle infezioni da clostridium difficile |
EP3720457A1 (fr) * | 2017-12-06 | 2020-10-14 | Lac2Biome S.R.L. | Composition à base de probiotiques et ses utilisations |
CN111973636A (zh) * | 2019-05-21 | 2020-11-24 | 王飞 | 一种肛肠凝胶及其制备方法 |
US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
EP4125972A1 (fr) * | 2020-03-31 | 2023-02-08 | Servatus Ltd | Polythérapie pour maladie inflammatoire de l'intestin |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0517363A (ja) | 1991-07-11 | 1993-01-26 | Yakult Honsha Co Ltd | 抗炎症剤及びそれを含有する化粧料 |
US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
CN1066926C (zh) | 1996-04-08 | 2001-06-13 | 钟春燕 | 将椰子水发酵制作的食用纤维及其生产方法 |
US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
CZ9900769A3 (cs) | 1999-03-04 | 2000-10-11 | Petr Ing. Drsc. Hušek | Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem |
US20020090416A1 (en) | 1999-03-09 | 2002-07-11 | Philip Connolly | Method of enhancing absorption and utilization of protein |
IT1307850B1 (it) | 1999-03-15 | 2001-11-19 | Italmed Di Galli Giovanna E Pa | Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio |
EP1145643A1 (fr) | 2000-04-10 | 2001-10-17 | Phillip Connolly | Concentré de lactoprotéines amelioré |
US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
RU2182008C1 (ru) | 2000-10-20 | 2002-05-10 | Самойленко Игорь Иннокентьевич | Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии |
US20030092163A1 (en) | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
FI20020078A (fi) | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
US6881419B2 (en) | 2002-04-09 | 2005-04-19 | William E. Lovett | Vitamin formulation for enhancing bone strength |
EP1539192A1 (fr) | 2002-04-24 | 2005-06-15 | Medicarb AB | Composition et ensemble de traitement de maladies intestinales inflammatoires |
DE60330781D1 (de) | 2002-08-06 | 2010-02-11 | Danisco | Anwendung von lactobacillus zur herstellung von exopolysacchariden in nahrungsmittel und pharmazeutische zusammensetzungen |
AU2002951270A0 (en) | 2002-09-06 | 2002-09-19 | Vri Biomedical Ltd | Probiotic Bacterium and Methods of Use |
WO2005001109A2 (fr) | 2003-05-06 | 2005-01-06 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Procedes et compositions permettant de detecter des microbes dans des echantillons fecaux |
US20100112088A1 (en) | 2003-08-29 | 2010-05-06 | Jay Pravda | Materials and methods for treatment of disorders associated with oxidative stress |
CA2557543A1 (fr) | 2004-02-27 | 2005-09-09 | Stichting Laboratorium Voor Infectieziekten | Methode de detection de micro-organisme dans un echantillon fecal |
EP1722804B1 (fr) * | 2004-03-04 | 2015-01-21 | E-L Management Corp. | Methode de traitement de la peau au moyen d'extrait de lactobacillus |
US20090197249A1 (en) | 2004-11-01 | 2009-08-06 | George Mason University | Compositions and methods for diagnosing colon disorders |
JP5788631B2 (ja) | 2005-04-06 | 2015-10-07 | ネステク ソシエテ アノニム | グルコース制御およびインスリン作用を栄養的に改善するための方法および組成物 |
FI20051319L (fi) | 2005-12-22 | 2007-06-23 | Cyflo Oy | Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi |
CN1840206A (zh) | 2006-01-19 | 2006-10-04 | 上海交通大学 | 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法 |
WO2007097323A1 (fr) | 2006-02-21 | 2007-08-30 | National University Corporation University Of Toyama | Procede rapide d'identification du microorganisme responsable d'une maladie infectieuse |
EP1992645A4 (fr) * | 2006-02-24 | 2011-03-09 | Q P Corp | Nouvel acide hyaluronique a faible poids moleculaire et/ou sel de celui-ci, et preparation cosmetique, composition pharmaceutique et composition alimentaire chacune utilisant ledit acide |
WO2007140621A1 (fr) | 2006-06-09 | 2007-12-13 | Nutravital Inc. | Compositions probiotiques et leurs utilisations |
US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
US20080081035A1 (en) | 2006-10-03 | 2008-04-03 | National Enzyme Company | Therapeutic protease compositions |
WO2008076975A1 (fr) | 2006-12-18 | 2008-06-26 | Advanced Bionutrition Corporation | Produit alimentaire sec contenant un probiotique vivant |
EP1972208A1 (fr) | 2007-03-16 | 2008-09-24 | Kirin Holdings Kabushiki Kaisha | Composition pour améliorer la flore microbienne intestinale |
JP2010522246A (ja) | 2007-03-27 | 2010-07-01 | ザ プロクター アンド ギャンブル カンパニー | プロバイオティクスを投与するための方法及びキット |
WO2008148798A2 (fr) | 2007-06-04 | 2008-12-11 | Egalet A/S | Compositions pharmaceutiques à libération contrôlée pour un effet prolongé |
ATE498325T1 (de) | 2007-07-06 | 2011-03-15 | Nutricia Nv | Verwendung von probiotika und ballaststoffen bei diarrhö |
US8193155B2 (en) * | 2009-02-09 | 2012-06-05 | Elc Management, Llc | Method and compositions for treating skin |
US20090098088A1 (en) | 2007-10-10 | 2009-04-16 | The Procter & Gamble Company | Methods And Kits For The Treatment Of Diverticular Conditions |
CN101240315A (zh) | 2008-02-21 | 2008-08-13 | 上海交通大学 | 检测药物防癌效果的非损伤性分子方法 |
RU2010143460A (ru) | 2008-05-01 | 2012-06-10 | Дзе Проктер Энд Гэмбл Компани (US) | Способы и наборы для терапии восстановительных состояний кишечника |
WO2010008272A1 (fr) | 2008-07-15 | 2010-01-21 | N.V. Nutricia | Traitement de troubles du transit intestinal |
JP2010161944A (ja) | 2009-01-13 | 2010-07-29 | Syngen Biotech Co Ltd | 新型カゼイ菌の亜種(sg96)及びこれを含有する菌抑制組成物及びその用途 |
EP2403510B1 (fr) | 2009-03-05 | 2020-02-26 | Probiotical S.p.A. | Souches bactériennes ayant une grande activité anti-inflammatoire |
WO2010103132A1 (fr) | 2009-03-10 | 2010-09-16 | Hero España, S.A. | Isolement, identification et caractérisation de souches ayant une activité probiotique à partir de fèces de nourrissons alimentés exclusivement avec du lait maternel |
AU2010299552A1 (en) * | 2009-09-23 | 2012-04-05 | Thomas Julius Borody | Therapy for enteric infections |
JP6006117B2 (ja) | 2009-11-12 | 2016-10-12 | ネステク ソシエテ アノニム | 腸内微生物叢バランス及び健康を促進するための栄養組成物 |
JP5932662B2 (ja) | 2009-12-22 | 2016-06-08 | プロビ アクティエボラーグ | 穀物ベースフラクション及びプロバイオティックを含む非発酵組成物、並びにそれらの使用 |
US8575130B2 (en) * | 2010-01-04 | 2013-11-05 | Holy Stone Healthcare Co., Ltd. | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease |
ITUD20100112A1 (it) * | 2010-06-09 | 2011-12-10 | Farma Derma S R L | Preparazione per uso vaginale e rettale e relativo procedimento di produzione |
US11235008B2 (en) | 2011-03-31 | 2022-02-01 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
US20140072621A1 (en) | 2011-05-09 | 2014-03-13 | The Cleveland Clinic Foundation | Composition and method to improve intestinal health |
GB201219873D0 (en) | 2012-11-05 | 2012-12-19 | Multigerm Uk Entpr Ltd | Diverticulitis treatment |
CN102919922A (zh) | 2012-11-08 | 2013-02-13 | 黑龙江省轻工科学研究院 | 一种复合益生菌发酵蓝莓果汁粉的制备方法 |
JP2016511272A (ja) | 2013-03-05 | 2016-04-14 | レイクスユニフェルシテイト フローニンゲン | 炎症を抑制するためのフィーカリバクテリウム・パラウスニッチィーhtf−f(dsm26943)の使用 |
JP6643984B2 (ja) | 2013-07-02 | 2020-02-12 | オーストリアノヴァ シンガポール プライベート リミテッド | カプセル化細胞を凍結乾燥する方法、凍結乾燥されたカプセル化細胞、凍結乾燥されたカプセル化細胞を含む組成物、ならびに、そのような細胞および組成物の使用 |
ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
ITMI20131473A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale |
MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
AU2015258769A1 (en) | 2014-05-12 | 2016-12-01 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
PL2990045T3 (pl) | 2014-08-26 | 2017-05-31 | Chr. Hansen A/S | Bifidobacterium animalis podgat. lactis do stosowania w zmniejszaniu bólu brzucha u kobiet po menopauzie |
MA45327A (fr) | 2016-05-13 | 2019-03-20 | Sofar Spa | Utilisation de probiotiques pour améliorer l'absorption des protéines |
WO2017195182A1 (fr) | 2016-05-13 | 2017-11-16 | Sofar S.P.A. | Utilisation de probiotiques pour améliorer l'absorption des protéines |
MA45288A (fr) | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
WO2018109520A1 (fr) | 2016-12-16 | 2018-06-21 | Compagnie Gervais Danone | Composition probiotique comprenant des souches de lactobacillus rhamnosus et de lactobacillus paracasei |
WO2019019961A1 (fr) | 2017-07-26 | 2019-01-31 | 海思科医药集团股份有限公司 | Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation |
IT201700101704A1 (it) | 2017-09-12 | 2019-03-12 | Sofar Spa | Nuovo uso per trattamento delle infezioni da clostridium difficile |
EP3720457A1 (fr) | 2017-12-06 | 2020-10-14 | Lac2Biome S.R.L. | Composition à base de probiotiques et ses utilisations |
CN108743851A (zh) | 2018-08-09 | 2018-11-06 | 深圳市博奥生物科技有限公司 | 一种复合益生菌粉的制备方法及复合益生菌粉 |
IT201900016850A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori |
IT201900016811A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali |
IT201900016865A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Composizioni a base di ceppi batterici e loro uso come antinfiammatori |
IT201900016805A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali |
US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
IT201900020422A1 (it) | 2019-11-05 | 2021-05-05 | Sofar Spa | Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine |
-
2015
- 2015-04-21 MA MA039710A patent/MA39710A/fr unknown
- 2015-04-22 WO PCT/IB2015/052938 patent/WO2015162570A1/fr active Application Filing
- 2015-04-22 US US15/305,470 patent/US11464814B2/en active Active
- 2015-04-22 JP JP2016564193A patent/JP2017513906A/ja active Pending
- 2015-04-22 CA CA2944118A patent/CA2944118C/fr active Active
- 2015-04-22 EP EP15726329.4A patent/EP3134072A1/fr active Pending
-
2022
- 2022-10-06 US US17/961,478 patent/US20230052820A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2944118A1 (fr) | 2015-10-29 |
US20170035816A1 (en) | 2017-02-09 |
US20230052820A1 (en) | 2023-02-16 |
WO2015162570A1 (fr) | 2015-10-29 |
EP3134072A1 (fr) | 2017-03-01 |
JP2017513906A (ja) | 2017-06-01 |
CA2944118C (fr) | 2020-06-30 |
US11464814B2 (en) | 2022-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
TW201613901A (en) | New compounds | |
IN2015DN01156A (fr) | ||
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
PH12016501702B1 (en) | Pyrazole amide derivative | |
MX2015015518A (es) | Metodos y composiciones para el tratamiento del cancer. | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2019000677A (es) | Células miméticas de células b. | |
IL251687B (en) | Medicinal composition for use in treatment to prevent vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery | |
MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
WO2016083315A8 (fr) | Utilisation d'antagonistes d'ox1r pour le traitement de maladies intestinales inflammatoires | |
PH12015502305A1 (en) | Use of pidotimod to treat inflammatory bowel disease | |
MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
IN2013MU03855A (fr) | ||
UA93635U (uk) | Фармацевтична композиція для лікування хронічних обструктивних захворювань легень | |
IN2014CH00035A (fr) |